​
​

Brainstorm Cell Therapeutics Ownership | Who Owns Brainstorm Cell Therapeutics?

OverviewRevenueFinancialsChartTranscripts

Brainstorm Cell Therapeutics Ownership Summary

Brainstorm Cell Therapeutics is owned by 18.65% institutional investors, 9.04% insiders, and 72.31% retail investors. Armistice capital is the largest institutional shareholder, holding 12.23% of BCLI shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.33% of its assets in Brainstorm Cell Therapeutics shares.

BCLI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockBrainstorm Cell Therapeutics18.65%9.04%72.31%
SectorHealthcare Stocks 47.25%8.01%44.75%
IndustryBiotech Stocks 45.35%7.81%46.83%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv70.73K1.33%7.00
Fidelity Extended Market Index436.04K0.55%101.84K
Vanguard Institutional Extnd Mkt Idx Tr401.01K0.50%-
Fidelity Series Total Market Index100.49K0.13%54.53K
NT Ext Equity Mkt Idx Fd - L79.81K0.10%-
BlackRock Extended Equity Market K62.75K0.08%-27.00
Fidelity Nasdaq Composite Index48.73K0.06%-
Fidelity Total Market Index47.81K0.06%-
Vanguard Instl Ttl Stck Mkt Idx Tr33.75K0.04%-
NT Ext Equity Mkt Idx Fd - NL30.05K0.04%-

Recent Insider Transactions

DateNameRoleActivityValue
Oct 01, 2024Lebovits Chaim President & CEOBuy$6.29K
Sep 30, 2024Lebovits Chaim President & CEOBuy$5.02K
May 28, 2024Lebovits Chaim President & CEOBuy$7.77K
May 21, 2024Lebovits Chaim President & CEOBuy$14.47K
May 22, 2024Lebovits Chaim President & CEOBuy$16.00K

Insider Transactions Trends

DateBuySell
2024 Q41-
2024 Q311
2024 Q211-
2024 Q1--
2023 Q31-

BCLI Ownership FAQ

Who Owns Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics shareholders are primarily institutional investors at 18.65%, followed by 9.04% insiders and 72.31% retail investors. The average institutional ownership in Brainstorm Cell Therapeutics's industry, Biotech Stocks , is 45.35%, which Brainstorm Cell Therapeutics falls below.

Who owns the most shares of Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics’s largest shareholders are Armistice capital (7.92M shares, 12.23%), Vanguard group (1.51M shares, 2.33%), and Geode capital management (484.28K shares, 0.75%). Together, they hold 15.31% of Brainstorm Cell Therapeutics’s total shares outstanding.

Does Blackrock own Brainstorm Cell Therapeutics?

Yes, BlackRock owns 0.60% of Brainstorm Cell Therapeutics, totaling 386.41K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 130.8K$. In the last quarter, BlackRock decreased its holdings by -103K shares, a -21.03% change.

Who is Brainstorm Cell Therapeutics’s biggest shareholder by percentage of total assets invested?

Armistice capital is Brainstorm Cell Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.03% of its assets in 7.92M Brainstorm Cell Therapeutics shares, valued at 2.68M$.

Who is the top mutual fund holder of Brainstorm Cell Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Brainstorm Cell Therapeutics shares, with 1.33% of its total shares outstanding invested in 70.73K Brainstorm Cell Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools